Evaluation of hypoxia-specific cytotoxic bioreductive agent-sodium borocaptate-10B conjugates as10B-carriers in boron neutron capture therapy


To evaluate the usefulness of 5 new10B-compounds (TX-2091, TX-2095, TX-2097, TX-2100, and TX-2110) as10B-carriers in boron neutron capture therpy (BNCT). They were conjugates that had been synthesized from a hypoxia-specific cytotoxic bioreductive agent, quinoxaline oxide TX-402 and a clinically used10B-carrier, sodium borocaptate-10B (BSH). The 5 new… (More)
DOI: 10.1007/BF02493275

8 Figures and Tables


  • Presentations referencing similar topics